Latest news


Partners4Access announces second gene therapy webinar on U.S. lessons learnt from Luxturna and Kymriah

Complementary webinar will be held on Wednesday April 4 2018 at 17:00 GMT/12:00 EST/9:00 PST. Registration available at PARTNERS4ACCESS has announced details of its upcoming webinar titled ` Gene Therapy – U.S. Lessons learnt from Luxturna & Kymriah’. This is the second in a three-part webinar series on Gene Therapy. This 60 min webinar […]

Read More


Gene Therapy Mind Map

On Rare Disease Day, we at P4A are exploring the most innovative ways to treat and cure rare diseases. This has led  to the creation of a Gene Therapy Mind Map, a learning resource to understand the different types and benefits of gene therapy. What is a Gene Therapy mind map? The Gene Therapy Mind […]

Read More


Dear orphan drug industry, are you prepared?

Rare Disease Day infographic – US & EU February 28 is rare disease day. To be rare is to be unique. And a rare disease area requires an innovative solution to access. To commemorate this day, Partners4Access are publishing two infographics focusing on key aspects that impact commercialization of orphan drugs. The infographics capture three […]

Read More


Partners4Access & Global Pricing Innovations expand UK presence with move to larger premises

New office accommodates higher headcount reflecting rapid growth for both companies Partners4Access (P4A), the global specialists in orphan drug access and Global Pricing Innovations (GPI), the pricing experts have moved their London headquarters to 120 New Cavendish Street. Both P4A and GPI have seen a rapid expansion in their client base throughout 2017. The  larger […]

Read More


Cancer treatments: A brief history

February 4 was World Cancer Day and here at Partners4Access, we are having a look back at how cancer treatments have evolved through the years and where they are likely to go in the future. First came surgery In the 18th century, surgery was hailed as the first effective cancer treatment. The discovery of anesthesia […]

Read More


Biopharma 2018 Success Kit: 11 months to go, 6 rare disease trends to watch!

For the rapidly developing orphan drug market, change is a constant. From new technologies to discussions over pricing, the estimated $137 billion market will witness new challenges for biopharma companies in the rare disease space. In a bid to unravel these barriers and with 11 months more to go in 2018, the team at Partners4Access […]

Read More


Though there is some way to go, NICE is moving in the right direction on HTAs

  From 1 March 2000 to 31 December 2017, NICE (National Institute for Health and Care Excellence) published over 800 healthcare technology recommendations. In total, 81% of those decisions were recommended, optimized or recommended for use in the Cancer Drugs Fund (CDF). Why then is NICE considered such a tough cookie when it comes to […]

Read More


Orphan Drug Pricing: Is Eurordis call to reduce prices by 3-5 times the answer to unequitable access?

Partners4Access comments on the new Eurordis Position Paper Earlier this month Eurordis published its position paper on orphan drug access. Whilst the report is commendable in pushing to drive equitable access for patients; their call to reduce orphan drug prices by 3 to 5 times by 2025 is no guarantee of full patient access. Affordability […]

Read More


Partners4Access launch weekly newsletter focusing on market access and rare diseases

Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market access landscape. The service will offer a comprehensive weekly summary of the most interesting and relevant news articles, beginning on Thursday 16th November 2017. The newsletter will allow readers to […]

Read More


P4A’s Sophie Schmitz presents key insights on Gene Therapy at WODC 2017

Sophie Schmitz, Managing Partner of Partners4Access, the specialists in orphan drug access, is presenting at the 8th annual meeting of the World Orphan Drug Congress in Barcelona on November 15, 2017 on Gene Therapy. Schmitz will be reviewing the potential of Gene Therapy to revolutionise the healthcare industry, highlighting recent successes and discussing key challenges. “Gene […]

Read More